Prognostic impact of steatosis in the clinical course of chronic HCV infection-Results from the German Hepatitis C-Registry
Please always quote using this URN: urn:nbn:de:bvb:20-opus-300549
- Background Liver steatosis is often observed in chronic HCV infection and associated to genotype or comorbidities. NAFLD is an important risk factor for end-stage liver disease. We aimed to analyse the course of NAFLD as a concomitant disease in a cohort of HCV patients. Methods The German Hepatitis C-Registry is a national multicenter real-world cohort. In the current analysis, 8789 HCV patients were included and separated based on the presence of steatosis on ultrasound and/or histology. Fibrosis progression was assessed by transientBackground Liver steatosis is often observed in chronic HCV infection and associated to genotype or comorbidities. NAFLD is an important risk factor for end-stage liver disease. We aimed to analyse the course of NAFLD as a concomitant disease in a cohort of HCV patients. Methods The German Hepatitis C-Registry is a national multicenter real-world cohort. In the current analysis, 8789 HCV patients were included and separated based on the presence of steatosis on ultrasound and/or histology. Fibrosis progression was assessed by transient elastography (TE), ultrasound or non-invasive surrogate scores. Results At the time of study inclusion 12.3% (n = 962) of HCV patients presented with steatosis (+S) (higher rate in GT-3). Diabetes mellitus was more frequent in GT-1 patients. HCV patients without steatosis (-S) had a slightly higher rate of fibrosis progression (FP) over time (30.3%) in contrast to HCV patients +S (26%). This effect was mainly observed in GT-3 patients (34.4% vs. 20.6%). A larger decrease of ALT, AST and GGT from baseline to FU-1 (4–24 weeks after EOT) was found in HCV patients (without FP) +S compared to -S. HCV patients -S and with FP presented more often metabolic comorbidities with a significantly higher BMI (+0.58kg/m\(^{2}\)) compared to patients -S without FP. This was particularly pronounced in patients with abnormal ALT. Conclusion Clinically diagnosed steatosis in HCV patients does not seem to contribute to significant FP in this unique cohort. The low prevalence of steatosis could reflect a lower awareness of fatty liver in HCV patients, as patients -S and with FP presented more metabolic risk factors.…
Author: | Monika Rau, Peter Buggisch, Stefan Mauss, Klaus H. W. Boeker, Hartwig Klinker, Tobias Müller, Albrecht Stoehr, Jörn M. Schattenberg, Andreas Geier |
---|---|
URN: | urn:nbn:de:bvb:20-opus-300549 |
Document Type: | Journal article |
Faculties: | Medizinische Fakultät / Medizinische Klinik und Poliklinik II |
Language: | English |
Parent Title (English): | PLoS ONE |
Year of Completion: | 2022 |
Volume: | 17 |
Issue: | 6 |
Article Number: | e0264741 |
Source: | PLoS ONE 2022, 17(6):e0264741. DOI: 10.1371/journal.pone.0264741 |
DOI: | https://doi.org/10.1371/journal.pone.0264741 |
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Tag: | HCV infection; liver; steatosis |
Release Date: | 2023/04/04 |
Collections: | Open-Access-Publikationsfonds / Förderzeitraum 2022 |
Licence (German): | CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |